How Is Peripheral Neuropathy Pain Treated in Amyloidosis?
At a Glance
Treatment for amyloidosis-related nerve pain aims to slow further nerve damage and ease symptoms. Care is individualized by amyloidosis type and kidney, heart, and blood-pressure health, with daily foot protection, physical therapy, and fall prevention.
In this answer
3 sections
Peripheral neuropathy—which often causes burning pain, numbness, and tingling in the feet—is one of the most challenging symptoms of amyloidosis. However, nerve pain in people with amyloidosis can also be caused by other factors, such as diabetes, vitamin deficiencies, or even the medications used to treat the amyloidosis itself [1].
Managing this pain requires a two-part approach: using specific pain medications to relieve your daily discomfort, and using disease-modifying treatments to stop the amyloid protein from causing further nerve damage. Alongside medication, practical steps like proper footwear and physical therapy are essential for protecting your feet and preventing falls.
Stopping the Nerve Damage: Disease-Modifying Treatments
Treating the underlying cause of your amyloidosis is the most effective way to prevent peripheral neuropathy from getting worse [2]. The correct approach depends on which type of amyloidosis you have, your specific symptoms, and your overall health [2]:
- Hereditary ATTR (hATTR) amyloidosis: For this genetic type, medications called gene silencers (such as patisiran, vutrisiran, and inotersen) reduce the liver’s production of the transthyretin (TTR) protein before it can misfold and damage nerves [3][4]. Clinical trials show these therapies can slow or halt progressive nerve damage [5]. While some patients experience improvements in neurologic function over time, existing nerve damage may be permanent, and results vary depending on how early treatment begins [6]. These drugs require careful monitoring by your care team, such as taking prescribed vitamin A supplements (for gene silencers) or monitoring kidney and platelet function (for inotersen) [4][7].
- AL (Light Chain) amyloidosis: Treatment involves therapies directed at the plasma cells (a type of white blood cell in the bone marrow), such as combination chemotherapy regimens, targeted immunotherapies (like daratumumab), or stem cell transplants in carefully selected patients [8][9]. The goal is to quickly lower the production of toxic light chains (abnormal antibody fragments) [10]. Notably, a common AL treatment called bortezomib can actually cause or worsen peripheral neuropathy [1][11]. If you develop nerve pain, your hematology team may adjust your dose or switch your regimen to protect your nerves—but you should never stop or change your regimen without their guidance [1].
Medications to Calm Nerve Pain
While disease-modifying therapies treat the underlying condition, they do not provide immediate pain relief. For burning or shooting pain, doctors prescribe medications that change how damaged nerves send pain signals to your brain [12]. These medications can take days or weeks to work and require gradual dose adjustments.
The safest option is highly individualized and must be chosen by your doctor based on your kidney function, heart health, and other conditions [13]:
- Nerve pain medications (Gabapentinoids): Drugs like gabapentin and pregabalin are common options for neuropathic pain [13][12]. They can significantly reduce nerve pain, but they must be adjusted carefully based on your kidney function [14]. Side effects can include dizziness, sleepiness, and leg swelling, which can compound balance issues and increase fall risk when mixed with other sedating medicines [14].
- Antidepressants for pain: Medications such as duloxetine (an SNRI, or serotonin-norepinephrine reuptake inhibitor) or amitriptyline (a tricyclic antidepressant) are also effective options [12][13]. However, they must be used carefully. Duloxetine can cause orthostatic hypotension (a drop in blood pressure upon standing) and is unsuitable for those with severe kidney or liver disease [15]. Amitriptyline is generally avoided if you have autonomic neuropathy (damage to the nerves controlling involuntary functions like blood pressure or heart rate), as it can worsen sudden drops in blood pressure, cause severe sedation, and affect heart rhythms [16].
- Topical treatments: Numbing patches (like 5% lidocaine) can be applied directly to intact skin on the feet for localized pain [12]. Because very little of the drug enters the bloodstream, the risk of systemic side effects is low [17]. Note that high-strength capsaicin patches (8%) are different; they cause intense burning initially and must be applied in a clinic by a healthcare professional [12]. Never apply any patch to an ulcer, open wound, or infected skin.
- Opioids: Strong pain medications like tramadol or methadone are typically avoided or used only as a last resort [13]. Tramadol carries risks of seizures and dangerous interactions with antidepressants, while methadone requires specialist prescribing and monitoring for dangerous heart rhythm effects [18]. Opioids also cause sedation, breathing depression, constipation, and increase the risk of falls [19].
Protecting Your Feet and Preventing Falls
Because peripheral neuropathy causes numbness (loss of protective sensation), you might not feel a cut or sore. Drawing on standards established for diabetic neuropathy care, taking strict precautions can help prevent small injuries from developing into serious ulcers [20].
Daily Foot Care Action Plan
- Inspect daily: Check the tops and bottoms of your feet daily. Use a mirror or ask a caregiver to help if you cannot see the bottoms [20].
- Check inside your shoes: Always feel the inside of your shoes for pebbles or rough seams before putting them on [20].
- Avoid heat damage: Do not use heating pads or very hot water on your feet, as you may not feel a burn [20].
- Do not perform “bathroom surgery”: Never cut calluses yourself or use over-the-counter chemical corn removers. Regular visits to a podiatrist are strongly recommended [20].
- Wear protective footwear: Never walk barefoot. Wear shoes with a wide toe box, good support, and no pressure points [21][22].
- Urgent Care: Contact your clinical team immediately if you notice a new open wound, blister, severe swelling, redness, warmth, foul odor, or black/blue discoloration on your foot.
Fall Prevention and Balance
Numbness impairs your balance, but fall risk in amyloidosis is also heavily influenced by orthostatic hypotension (a sudden drop in blood pressure when standing, causing dizziness) and side effects from sedating pain medications [23][24].
- Physical therapy: Ask your doctor for a referral to a physical therapist for a supervised balance and gait assessment [25]. Do not try to challenge your balance on your own or walk with your eyes closed.
- Walking aids: If you are stumbling or feel unstable, a therapist can properly fit you for orthotics (custom shoe inserts or joint supports), a cane, or a walker [26].
- Home modifications: An occupational therapist can evaluate your home and recommend removing throw rugs, improving lighting, or adding grab bars to make navigation safer [27].
Common questions in this guide
What is the main way to treat peripheral neuropathy pain in amyloidosis?
Can my amyloidosis treatment make nerve pain worse?
Which pain medicines are used for amyloidosis-related nerve pain?
How can I protect my feet if amyloidosis has caused numbness?
How can I lower my risk of falls with amyloidosis neuropathy?
Could something besides amyloidosis be causing my nerve pain?
What monitoring do gene-silencing treatments require?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Show more
Get notified when new evidence is published on Amyloidosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Which specific type of amyloidosis is causing my peripheral neuropathy, or could other factors like my chemotherapy, diabetes, or vitamin levels be contributing?
- 2.Given my kidney function, heart health, and blood pressure, what is the safest pain medication for me to try?
- 3.Are any of my current treatments (like bortezomib) or pain medicines increasing my risk of falls or nerve damage?
- 4.Should I be evaluated by a podiatrist for specialized footwear to protect my numb feet?
- 5.Can you refer me to a physical therapist for a supervised balance assessment and to evaluate if a walking aid would help?
- 6.If I am taking a TTR-lowering medication (gene silencer), what is my specific plan for vitamin A supplementation and monitoring?
References
References (27)
- 1
Prevalence and predictors of neurological manifestations in systemic AL amyloidosis.
Thimm A, Carpinteiro A, Oubari S, et al.
Journal of the neurological sciences 2022; (440()):120341 doi:10.1016/j.jns.2022.120341.
PMID: 35872471 - 2
Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.
Gertz MA, Dispenzieri A
JAMA 2020; (324(1)):79-89 doi:10.1001/jama.2020.5493.
PMID: 32633805 - 3
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D, Gonzalez-Duarte A, O'Riordan WD, et al.
The New England journal of medicine 2018; (379(1)):11-21 doi:10.1056/NEJMoa1716153.
PMID: 29972753 - 4
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
Benson MD, Waddington-Cruz M, Berk JL, et al.
The New England journal of medicine 2018; (379(1)):22-31 doi:10.1056/NEJMoa1716793.
PMID: 29972757 - 5
Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
González-Duarte A, Berk JL, Quan D, et al.
Journal of neurology 2020; (267(3)):703-712 doi:10.1007/s00415-019-09602-8.
PMID: 31728713 - 6
Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.
Quan D, Obici L, Berk JL, et al.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2023; (30(1)):49-58 doi:10.1080/13506129.2022.2118043.
PMID: 36120830 - 7
A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database.
Liu Y, Li H, Hu C, et al.
Frontiers in pharmacology 2024; (15()):1368244 doi:10.3389/fphar.2024.1368244.
PMID: 38873427 - 8
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs 2022; (82(6)):683-690 doi:10.1007/s40265-022-01705-3.
PMID: 35416593 - 9
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines.
Sanchorawala V, Boccadoro M, Gertz M, et al.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2022; (29(1)):1-7 doi:10.1080/13506129.2021.2002841.
PMID: 34783272 - 10
Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
Ikura H, Endo J, Kitakata H, et al.
International journal of molecular sciences 2022; (23(11)) doi:10.3390/ijms23116336.
PMID: 35683015 - 11
The efficacy and safety of bortezomib-based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis.
Liu B, Bai M, Wang Y, et al.
European journal of internal medicine 2019; (69()):32-41 doi:10.1016/j.ejim.2019.08.011.
PMID: 31447275 - 12
Neuropathic pain: Evidence based recommendations.
Moisset X
Presse medicale (Paris, France : 1983) 2024; (53(2)):104232 doi:10.1016/j.lpm.2024.104232.
PMID: 38641202 - 13
Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis.
Soliman N, Moisset X, Ferraro MC, et al.
The Lancet. Neurology 2025; (24(5)):413-428 doi:10.1016/S1474-4422(25)00068-7.
PMID: 40252663 - 14
Gabapentin for chronic neuropathic pain in adults.
Wiffen PJ, Derry S, Bell RF, et al.
The Cochrane database of systematic reviews 2017; (6()):CD007938 doi:10.1002/14651858.CD007938.pub4.
PMID: 28597471 - 15
The Pharmacological Therapy of Chronic Neuropathic Pain.
Binder A, Baron R
Deutsches Arzteblatt international 2016; (113(37)):616-625.
PMID: 27697147 - 16
[Causes, spectrum, and treatment of the diabetic neuropathy].
Dohrn MF, Winter N, Dafotakis M
Der Nervenarzt 2020; (91(8)):714-721 doi:10.1007/s00115-020-00948-3.
PMID: 32647958 - 17
Topical Treatment of Peripheral Neuropathic Pain: Applying the Evidence.
Sommer C, Cruccu G
Journal of pain and symptom management 2017; (53(3)):614-629 doi:10.1016/j.jpainsymman.2016.09.015.
PMID: 28042075 - 18
Methadone in Cancer Pain.
Ramkiran S, Thota RS
Indian journal of palliative care 2020; (26(2)):215-220 doi:10.4103/0973-1075.285690.
PMID: 32874036 - 19
Evaluation of Effectiveness and Safety of Firstline Drugs Used in the Treatment of Peripheral Neuropathy Among Elderly Population-A Randomised, Open-label, Active Comparator Study.
Balasundaram MK, Kannauje PK, Dhaneria S, Singh A
Annals of neurosciences 2026; (33(1)):29-36 doi:10.1177/09727531241243126.
PMID: 39544662 - 20
Preventing diabetes-related foot ulcers through early detection of peripheral neuropathy.
McMorrow R, Nube VL, Manski-Nankervis JA
Australian journal of general practice 2022; (51(11)):833-838 doi:10.31128/AJGP-06-22-6456.
PMID: 36309996 - 21
Footwear in the causation and prevention of foot ulcers in diabetes mellitus.
Premkumar R, Rajan P, Rima J, Richard J
The National medical journal of India 2017; (30(5)):255-261 doi:10.4103/0970-258X.234391.
PMID: 29916424 - 22
Assessment of ulceration risk in diabetic individuals.
Dutra LMA, Novaes MRCG, Melo MC, et al.
Revista brasileira de enfermagem 2018; (71 Suppl 2()):733-739 doi:10.1590/0034-7167-2017-0337.
PMID: 29791638 - 23
Exercise Interventions for Individuals With Neurological Disorders: A Systematic Review of Systematic Reviews.
Lai CH, Chen HC, Liou TH, et al.
American journal of physical medicine & rehabilitation 2019; (98(10)):921-930 doi:10.1097/PHM.0000000000001247.
PMID: 31206360 - 24
Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management.
Palma JA, Gonzalez-Duarte A, Kaufmann H
Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2019; (29(Suppl 1)):33-44 doi:10.1007/s10286-019-00623-x.
PMID: 31452021 - 25
A Systematic Review of the Effect of Physical Rehabilitation on Balance in People with Diabetic Peripheral Neuropathy Who are at Risk of Falling.
Alissa N, Shipper AG, Zilliox L, Westlake KP
Clinical interventions in aging 2024; (19()):1325-1339 doi:10.2147/CIA.S459492.
PMID: 39050517 - 26
Epidemiology and Functional Impact of Early Peripheral Neuropathy Signs in Older Adults from a General Population.
Bronge W, Lindholm B, Elmståhl S, Siennicki-Lantz A
Gerontology 2024; (70(3)):257-268 doi:10.1159/000535620.
PMID: 38043521 - 27
The Effect of Individualized Fall Prevention Programs on Community-Dwelling Older Adults: A Scoping Review.
Boright LE, Arena SK, Wilson CM, McCloy L
Cureus 2022; (14(3)):e23713 doi:10.7759/cureus.23713.
PMID: 35510013
This page explains ways to manage amyloidosis-related nerve pain for informational purposes only and does not constitute medical advice. Your amyloidosis and pain-care teams should choose medicines and treatment changes based on your health.